Downgrades Buy Hold X

NEO NeoGenomics

The Benchmark Company

Initiated Buy X

NEO NeoGenomics

Jefferies

$22

Resumed Buy X

NEO NeoGenomics

Craig Hallum

$26

Reiterated Buy X

NEO NeoGenomics

BTIG Research

$25 $21

Upgrades Eq-Weight Overweight X

NEO NeoGenomics

Stephens

$18

Downgrades Outperform Mkt Perform X

NEO NeoGenomics

Raymond James

Upgrades Neutral Buy X

NEO NeoGenomics

BTIG Research

$25

Upgrades Hold Buy X

NEO NeoGenomics

The Benchmark Company

$20

Upgrades Hold Buy X

NEO NeoGenomics

Needham

$15

Downgrades Buy Hold X

NEO NeoGenomics

The Benchmark Company

Downgrades Buy Hold X

NEO NeoGenomics

Needham

Initiated Overweight X

NEO NeoGenomics

Piper Sandler

$13

Downgrades Buy Neutral X

NEO NeoGenomics

BofA Securities

$25 $18

Downgrades Overweight Eq-Weight X

NEO NeoGenomics

Stephens

$34 $16

Resumed Overweight X

NEO NeoGenomics

Stephens

$40

Initiated Outperform X

NEO NeoGenomics

Cowen

$42

Upgrades Mkt Perform Outperform X

NEO NeoGenomics

Raymond James

$53

Initiated Buy X

NEO NeoGenomics

Goldman

$55

Resumed Buy X

NEO NeoGenomics

Needham

$65

Downgrades Outperform Mkt Perform X

NEO NeoGenomics

Raymond James

Initiated Buy X

NEO NeoGenomics

Truist

$65

Reiterated Buy X

NEO NeoGenomics

Needham

$22 $24

Reiterated Buy X

NEO NeoGenomics

Needham

$19 $22

Initiated Buy X

NEO NeoGenomics

Needham

$14

Upgrades Outperform Strong Buy X

NEO NeoGenomics

First Analysis Sec

$18

Initiated Outperform X

NEO NeoGenomics

Leerink Partners

$18

Downgrades Overweight Eq-Weight X

NEO NeoGenomics

First Analysis Sec

$11

NEO  NeoGenomics, Inc.

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.